An update on the development of drugs against smallpox

Current Opinion in Investigational Drugs

Volumn 9, Issue 8, 2008, Pages 865-870

  Tse Dinh, Y C ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

DNA polymerase inhibitor; Nucleoside analog; Orthopoxvirus; Orthopoxvirus topoisomerase; Smallpox; Thymidine kinase

Indexed keywords

1 O OCTADECYL 2 O BENZYLGLYCEROCIDOFOVIR; 5 (2 BROMOVINYL) 2' DEOXYURIDINE; 9 (3 HYDROXY 2 PHOSPHONOMETHOXYPROPYL)ADENINE; ACICLOVIR; AMIDE; ARISTEROMYCIN; CANERTINIB; CIDOFOVIR; CMX 001; HEXADECYCLOXYPROPYLCIDOFOVIR; IMATINIB; N [3,3A,4,4A,5,5A,6,6A OCTAHYDRO 1,3 DIOXO 4,6 ETHENOCYCLOPROP[F]ISOINDOL 2(1H) YL]CARBOXAMIDE; N METHANOCARBATHYMIDINE; NEPLANOCIN A; PENCICLOVIR; ST 246; THYMIDINE DERIVATIVE; THYMIDINE KINASE; VACCINIA ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; BIOLOGICAL WARFARE; DRUG EFFICACY; DRUG MECHANISM; DRUG STRUCTURE; NONHUMAN; ORTHOPOXVIRUS; REVIEW; SIGNAL TRANSDUCTION; SMALLPOX; SMALLPOX VIRUS; VIRUS INFECTION;

ANIMALS; ANTIVIRAL AGENTS; BIOTERRORISM; DRUG DELIVERY SYSTEMS; DRUG DESIGN; DRUG THERAPY, COMBINATION; HUMANS; SIGNAL TRANSDUCTION; SMALLPOX; VARIOLA VIRUS;

EID: 48349146076     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (48)

1. Sliva K, Schnierle B: From actually toxic to highly specific - novel drugs against poxviruses. Virol J (2007) 4:8.
2. Prichard MN, Kern ER: Orthopoxvirus targets for the development of antiviral therapies. Curr Drug Targets Infect Disord (2005) 5(1):17-28. •• A comprehensive review of the orthopoxvirus replication cycle and the potential therapeutic targets in the viral genome.
3. Wallin A, Luksiene Z, Zagminas K, Surkiene G: Public health and bioterrorism: Renewed threat of anthrax and smallpox. Medicina (Kaunas) (2007) 43(4):278-284.
4. Stittelaar KJ, Neyts J, Naesens L, van Amerongen G, van Lavieren RF, Holý A, De Clercq E, Niesters HG, Fries E, Maas C, Mulder PG et al: Antiviral treatment is more effective than smallpox vaccination upon lethal monkeypox virus infection. Nature (2006) 439(7077):745- 748. •• This study provided support for the argument that, in addition to smallpox vaccination, antiviral drugs should be developed as a precaution.
5. Parker S, Nuara A, Buller RM, Schultz DA: Human monkeypox: An emerging zoonotic disease. Future Microbiol (2007) 2:17-34.
6. Wittek R: Vaccinia immune globulin: Current policies, preparedness, and product safety and efficacy. Int J Infect Dis (2006) 10(3):193-201.
7. De Clercq E: Acyclic nucleoside phosphonates: Past, present and future. Bridging chemistry to HIV, HBV, HCV, HPV, adeno-, herpes-, and poxvirus infections: The phosphonate bridge. Biochem Pharmacol (2007) 73(7):911-922.
8. Magee WC, Hostetler KY, Evans DH: Mechanism of inhibition of VV DNA polymerase by cidofovir diphosphate. Antimicrob Agents Chemother (2005) 49(8):3153-3162.
9. Parker S, Touchette E, Oberle C, Almond M, Robertson A, Trost LC, Lampert B, Painter G, Buller RM: Efficacy of therapeutic intervention with an oral ether-lipid analog of cidofovir (CMX-001) in a lethal mousepox model. Antiviral Res (2008) 77(1):39-49. • CMX-001 was characterized in a mousepox model. The compound is undergoing a phase I clinical trial for the treatment of smallpox infection.
10. Chimerix Inc: Chimerix initiates a multi-dose clinical trial of the company's lead compound, CMX-001, for the treatment for smallpox infection. Press Release (2007): December 11.
11. Lebeau I, Andrei G, Dal Pozzo F, Beadle JR, Hostetler KY, De Clercq E, van den Oord J, Snoeck R: Activities of alkoxyalkyl esters of cidofovir (CDV), cyclic CDV, and (S)-9-(3-hydroxy-2-phosphonylmethoxypropyl)adenine against orthopoxviruses in cell monolayers and in organotypic cultures. Antimicrob Agents Chemother (2006) 50(7):2525-2529.
12. Hostetler KY, Beadle JR, Trahan J, Aldern KA, Owens G, Schriewer J, Melman L, Buller RM: Oral 1-O-octadecyl-2 O-benzyl-sn-glycero-3-cidofovir targets the lung and is effective against a lethal respiratory challenge with ectromelia virus in mice. Antiviral Res (2007) 73(3):212-218. • This study showed that a modified form of cidofovir may have superior therapeutic properties compared with the unmodified drug.
13. Ruiz JC, Beadle JR, Aldern KA, Keith KA, Hartline CB, Kern ER, Hostetler KY: Synthesis and antiviral evaluation of alkoxyalkyl-phosphate conjugates of cidofovir and adefovir. Antiviral Res (2007) 75(1):87-90.
14. Beadle JR, Wan WB, Ciesla SL, Keith KA, Hartline C, Kern ER, Hostetler KY: Synthesis and antiviral evaluation of alkoxyalkyl derivatives of 9-(S)-(3-hydroxy-2-phosphonomethoxypropyl) adenine against cytomegalovirus and orthopoxviruses. J Med Chem (2006) 49(6):2010-2015.
15. Quenelle DC, Collins DJ, Herrod BP, Keith KA, Trahan J, Beadle JR, Hostetler KY, Kern ER: Effect of oral treatment with hexadecyloxypropyl-[( S)-9-(3-hydroxy-2-phosphonylmethoxypropyl) adenine] [(S)-HPMPA] or octadecyloxyethyl-(S)-HPMPA on cowpox or VV infections in mice. Antimicrob Agents Chemother (2007) 51(11):3940-3947. • This paper describes lipid-conjugated acyclic nucleoside phosphonates that are orally available and effective in the treatment of mice infected with orthopoxviruses.
16. Fan X, Zhang X, Zhou L, Keith KA, Kern ER, Torrence PF: Assembling a smallpox biodefense by interrogating 5-substituted pyrimidine nucleoside chemical space. Antiviral Res (2006) 71(2-3):201-205.
17. Fan X, Zhang X, Zhou L, Keith KA, Kern ER, Torrence PF: A pyrimidine-pyrazolone nucleoside chimera with potent in vitro anti-orthopoxvirus activity. Bioorg Med Chem Lett (2006) 16(12):3224-3228.
18. Fan X, Zhang X, Zhou L, Keith KA, Prichard MN, Kern ER, Torrence PF: Toward orthopoxvirus countermeasures: A novel heteromorphic nucleoside of unusual structure. J Med Chem (2006) 49(14):4052-4054.
19. Prichard MN, Keith KA, Johnson MP, Harden EA, McBrayer A, Luo M, Qiu S, Chattopadhyay D, Fan X, Torrence PF, Kern ER: Selective phosphorylation of antiviral drugs by VV thymidine kinase. Antimicrob Agents Chemother (2007) 51(5):1795-1803. • The results of this study demonstrated the important role of thymidine kinase selectivity in the efficacy of nucleoside-based antiviral drugs.
20. El Omari K, Solaroli N, Karlsson A, Balzarini J, Stammers DK: Structure of VV thymidine kinase in complex with dTTP: Insights for drug design. BMC Struct Biol (2006) 6:22.
21. Prichard MN, Keith KA, Quenelle DC, Kern ER: Activity and mechanism of action of N-methanocarbathymidine against herpesvirus and orthopoxvirus infections. Antimicrob Agents Chemother (2006) 50(4):1336-1341.
22. Smee DF, Wandersee MK, Bailey KW, Wong MH, Chu CK, Gadthula S, Sidwell RW: Cell line dependency for antiviral activity and in vivo efficacy of N-methanocarbathymidine against orthopoxvirus infections in mice. Antiviral Res (2007) 73(1):69-77.
23. Smee DF, Hurst BL, Wong MH, Glazer RI, Rahman A, Sidwell RW: Efficacy of N-methanocarbathymidine in treating mice infected intranasally with the IHD and WR strains of VV. Antiviral Res (2007) 76(2):124-129.
24. Sauerbrei A, Meier C, Meerbach A, Schiel M, Helbig B, Wutzler P: In vitro activity of cycloSal-nucleoside monophosphates and polyhydroxycarboxylates against orthopoxviruses. Antiviral Res (2005) 67(3):147-154.
25. Sauerbrei A, Meier C, Meerbach A, Wutzler P: Inhibitory efficacy of cycloSal-nucleoside monophosphates of aciclovir and brivudin on DNA synthesis of orthopoxviruses. Antivir Chem Chemother (2006) 17(1):25-31.
26. De Clercq E: John Montgomery's legacy: Carbocyclic adenosine analogs as SAH hydrolase inhibitors with broad-spectrum antiviral activity. Nucleosides Nucleotides Nucleic Acids (2005) 24(10-12):1395-1415.
27. Yang M, Schneller SW: 5′-Homoaristeromycin. Synthesis and antiviral activity against orthopoxviruses. Bioorg Med Chem Lett (2005) 15(1):149-151.
28. Roy A, Schneller SW, Keith KA, Hartline CB, Kern ER: The 4′,4′-difluoro analog of 5′-noraristeromycin: A new structural prototype for possible antiviral drug development toward orthopoxvirus and cytomegalovirus. Bioorg Med Chem (2005) 13(14):4443-4449.
29. Arumugham B, Kim HJ, Prichard MN, Kern ER, Chu CK: Synthesis and antiviral activity of 7-deazaneplanocin A against orthopoxviruses (vaccinia and CV). Bioorg Med Chem Lett (2006) 16(2):285-287.
30. Tse-Dinh YC: Exploring DNA topoisomerases as targets of novel therapeutic agents in the treatment of infectious diseases. Infect Disord Drug Targets (2007) 7(1):3-9.
31. Bond A, Reichert Z, Stivers JT: Novel and specific inhibitors of a poxvirus type I topoisomerase. Mol Pharmacol (2006) 69(2):547-557.
32. Fujimoto DF, Pinilla C, Segall AM: New peptide inhibitors of type IB topoisomerases: Similarities and differences vis-a-vis inhibitors of tyrosine recombinases. J Mol Biol (2006) 363(5):891-907.
33. Da Fonseca F, Moss B: Poxvirus DNA topoisomerase knockout mutant exhibits decreased infectivity associated with reduced early transcription. Proc Natl Acad Sci USA (2003) 100(20):11291-11296.
34. Perry K, Hwang Y, Bushman FD, Van Duyne GD: Structural basis for specificity in the poxvirus topoisomerase. Mol Cell (2006) 23(3):343-354. • The topoisomerase enzyme crystallized in this study is encoded by the smallpox virus, instead of the more commonly used VV, which renders the determined structure potentially highly useful for differentiating substrate specificity.
35. Osheroff N: Unraveling the structure of the variola topoisomerase IB-DNA complex: A possible new twist on smallpox therapy. Mol Interv (2006) 6(5):245-248.
36. Bailey TR, Rippin SR, Opsitnick E, Burns CJ, Pevear DC, Collett MS, Rhodes G, Tohan S, Huggins JW, Baker RO, Kern ER et al: N-(3,3a,4,4a,5,5a,6, 6a-octahydro-1,3-dioxo-4,6-ethenocycloprop[f] isoindol-2-(1H)-yl)carboxamides: Identification of novel orthopoxvirus egress inhibitors. J Med Chem (2007) 50(7):1442-1444. • A novel family of extracellular enveloped virus egress inhibitors, which has entered phase I clinical trials is presented in this study.
37. Yang G, Pevear DC, Davies MH, Collett MS, Bailey T, Rippen S, Barone L, Burns C, Rhodes G, Tohan S, Huggins JW et al: An orally bioavailable antipoxvirus compound (ST-246) inhibits extracellular virus formation and protects mice from lethal orthopoxvirus challenge. J Virol (2005) 79(20):13139-13149.
38. Quenelle DC, Buller RM, Parker S, Keith KA, Hruby DE, Jordan R, Kern ER: Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice. Antimicrob Agents Chemother (2007) 51(2):689-695. •• This study presents results from animal studies using the highly promising egress inhibitor ST-246.
39. Sbrana E, Jordan R, Hruby DE, Mateo RI, Xiao SY, Siirin M, Newman PC, Da Rosa AP, Tesh RB: Efficacy of the antipoxvirus compound ST-246 for treatment of severe orthopoxvirus infection. Am J Trop Med Hyg (2007) 76(4):768-773.
40. Newsome TP, Weisswange I, Frischknecht F, Way M: Abl collaborates with Src family kinases to stimulate actin-based motility of VV. Cell Microbiol (2006) 8(2):233-241.
41. Reeves PM, Bommarius B, Lebeis S, McNulty S, Christensen J, Swimm A, Chahroudi A, Chavan R, Feinberg MB, Veach D, Bornmann W et al: Disabling poxvirus pathogenesis by inhibition of Abl-family tyrosine kinases. Nat Med (2005) 11(7):731-739.
42. Yang H, Kim SK, Kim M, Reche PA, Morehead TJ, Damon IK, Welsh RM, Reinherz EL: Antiviral chemotherapy facilitates control of poxvirus infections through inhibition of cellular signal transduction. J Clin Invest (2005) 115(2):379-387.
43. Silva PN, Soares JA, Brasil BS, Nogueira SV, Andrade AA, de Magalhães JC, Bonjardim MB, Ferreira PC, Kroon EG, Bruna-Romero O, Bonjardim CA: Differential role played by the MEK/ERK/EGR-1 pathway in orthopoxviruses vaccinia and cowpox biology. Biochem J (2006) 398(1):83-95.
44. Myskiw C, Deschambault Y, Jefferies K, He R, Cao J: Aurintricarboxylic acid inhibits the early stage of VV replication by targeting both cellular and viral factors. J Virol (2007) 81(6):3027-3032. •• This paper describes, for the first time, an antiviral compound that targets both cellular and viral factors leading to inhibition of viral replication.
45. Phan J, Tropea JE, Waugh DS: Structure-assisted discovery of Variola major H1 phosphatase inhibitors. Acta Crystallogr D Biol Crystallogr (2007) 63(6):698-704. • This study demonstrated how structural biology can be combined with molecular modeling to select initial lead compounds for smallpox virus treatment.
46. Remichkova M, Petrov N, Galabov AS: Synergistic combination effect of cidofovir and idoxuridine on VV replication. Antivir Chem Chemother (2006) 17(2):53-58.
47. Quenelle DC, Prichard MN, Keith KA, Hruby DE, Jordan R, Painter GR, Robertson A, Kern ER: Synergistic efficacy of the combination ST-246 with CMX-001 against orthopoxviruses. Antimicrob Agents Chemother (2007) 51(11):4118-4124. • The potential use of combination therapy to obtain synergistic efficacy in orthopoxvirus therapy was explored in this study.
48. Jordan R, Hruby D: Smallpox antiviral drug development: Satisfying the animal efficacy rule. Expert Rev Anti Infect Ther (2006) 4(2):277-289. •• This is an excellent review on the important issue of animal model selection in the evaluation of potential drug candidates for the treatment of smallpox virus infection.